Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics

[1]  S. Keir,et al.  Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[2]  Mark A. Brown,et al.  Hsp90--from signal transduction to cell transformation. , 2007, Biochemical and biophysical research communications.

[3]  H. Kato,et al.  Knock down of hSNF5/Ini1 causes cell cycle arrest and apoptosis in a p53-dependent manner. , 2007, Biochemical and biophysical research communications.

[4]  D. Zagzag,et al.  INI1 Induces Interferon Signaling and Spindle Checkpoint in Rhabdoid Tumors , 2007, Clinical Cancer Research.

[5]  O. Delattre,et al.  Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. , 2007, The Biochemical journal.

[6]  F. Heppner,et al.  Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. , 2007, European journal of cancer.

[7]  L. Neckers,et al.  Heat shock protein 90: The cancer chaperone , 2007, Journal of Biosciences.

[8]  Y. Oda,et al.  Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR , 2007, Journal of Cancer Research and Clinical Oncology.

[9]  C. Lanvers-Kaminsky,et al.  Inhibitors of histone deacetylases as potential therapeutic tools for high‐risk embryonal tumors of the nervous system of childhood , 2007, International journal of cancer.

[10]  J. McCubrey,et al.  The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion , 2007, Leukemia.

[11]  L. Neckers,et al.  Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells , 2007, Clinical Cancer Research.

[12]  D. Yee,et al.  Targeting insulin-like growth factor pathways. , 2007, British journal of cancer.

[13]  P. Workman,et al.  Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. , 2006, Endocrine-related cancer.

[14]  C. Dominici,et al.  Down-Regulation of Insulin-Like Growth Factor I Receptor Activity by NVP-AEW541 Has an Antitumor Effect on Neuroblastoma Cells In vitro and In vivo , 2006, Clinical Cancer Research.

[15]  O. Delattre,et al.  The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells. , 2006, European journal of cancer.

[16]  K. Foster,et al.  Members of the hSWI/SNF chromatin remodeling complex associate with and are phosphorylated by protein kinase B/Akt , 2006, Oncogene.

[17]  S. Knox,et al.  Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. , 2006, International journal of radiation oncology, biology, physics.

[18]  A. Fusco,et al.  Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. , 2006, Cancer research.

[19]  Paul Workman,et al.  Inhibitors of the HSP90 molecular chaperone: current status. , 2006, Advances in cancer research.

[20]  L. Neckers.  Chaperoning oncogenes: Hsp90 as a target of geldanamycin. , 2006, Handbook of experimental pharmacology.

[21]  C. Conover,et al.  In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. , 2006, Cancer research.

[22]  D. Yee,et al.  Type I insulin-like growth factor receptor as a therapeutic target in cancer. , 2005, Cancer research.

[23]  B. Bodey,et al.  Epidermal growth factor receptor (EGFR) expression in childhood brain tumors. , 2005, In vivo.

[24]  Y. Pommier,et al.  Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells , 2005, Breast Cancer Research.

[25]  M. Rosenblum,et al.  INI1 Protein Expression Distinguishes Atypical Teratoid/Rhabdoid Tumor from Choroid Plexus Carcinoma , 2005, Journal of neuropathology and experimental neurology.

[26]  U. Schüller,et al.  Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. , 2005, The American journal of pathology.

[27]  A. Narendran,et al.  Effects of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Bcr-Abl Status and Imatinib Mesylate Sensitivity , 2005, Pediatric Research.

[28]  K. Asadullah,et al.  Different release of cytokines into the cerebrospinal fluid following surgery for intra- and extra-axial brain tumours , 2005, Acta Neurochirurgica.

[29]  D. Fabbro,et al.  In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. , 2004, Cancer cell.

[30]  Salisbury Aj,et al.  Development of molecular agents for IGF receptor targeting. , 2003 .

[31]  D. George.  Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. , 2003, Advances in experimental medicine and biology.

[32]  H. Uramoto,et al.  Regulatory mechanisms for the expression and activity of platelet-derived growth factor receptor. , 2003, Acta biochimica Polonica.

[33]  Min-Cheol Lee,et al.  Atypical teratoid/rhabdoid tumor of the central nervous system: Clinico‐pathological study , 2002, Neuropathology : official journal of the Japanese Society of Neuropathology.

[34]  O. Delattre,et al.  A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle , 2002, Oncogene.

[35]  V. Pulkkinen,et al.  Expression of insulin-like growth factors IGF-I and IGF-II, and their receptors during the growth and megakaryocytic differentiation of K562 cells. , 2002, Leukemia research.

[36]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[37]  C. Roberts,et al.  The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. , 2002, Cancer research.

[38]  A. Sands,et al.  Disruption of Ini1 Leads to Peri-Implantation Lethality and Tumorigenesis in Mice , 2001, Molecular and Cellular Biology.

[39]  S. Ogino,et al.  Comparative Immunohistochemical Study of Insulin-like Growth Factor II and Insulin-like Growth Factor ReceptorType 1 in Pediatric Brain Tumors , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[40]  M. Yaniv,et al.  The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression , 2000, EMBO reports.

[41]  E. Wilkinson,et al.  CSF cytology of atypical teratoid/rhabdoid tumor of the brain in a two‐year‐old girl: A case report , 2000, Diagnostic cytopathology.

[42]  J. Biegel,et al.  Germline INI1 mutation in a patient with a central nervous system atypical teratoid tumor and renal rhabdoid tumor , 2000, Genes, chromosomes & cancer.

[43]  J. Biegel,et al.  Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. , 1999, Cancer research.

[44]  D. Leroith,et al.  Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. , 1998, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[45]  F. Thorsen,et al.  Brain tumor cell invasion, anatomical and biological considerations. , 1997, Anticancer research.

[46]  B. Ursø,et al.  The Insulin-Like Growth Factor-I Receptor , 1994, Hormone Research.

[47]  L. Rorke.  Classification of central nervous system tumors in children. , 1987, Progress in experimental tumor research.